Literature DB >> 27537855

Should gentamicin trough levels be routinely obtained in term neonates?

J Ibrahim1, D Maffei2, G El-Chaar3,4, S Islam5, S Ponnaiya6, A Nayak7, W Rosenfeld6, N Hanna7.   

Abstract

OBJECTIVE: Gentamicin is a common antibiotic used to treat sepsis in neonates. We hypothesize that obtaining routine gentamicin trough levels may not be necessary in low-risk, term infants. STUDY
DESIGN: We performed a retrospective cohort study of term infants (n=346) treated with gentamicin in a single level III neonatal intensive care unit (NICU). The results of gentamicin trough levels and the correlation with risk factors and potential side effects were recorded. In addition, we conducted a survey of 75 academic NICUs across the United States regarding their gentamicin monitoring practice.
RESULTS: Routine trough levels did not predict potential gentamicin toxicity in neonates with low risk factors. Regression analysis demonstrated a positive correlation between gentamicin trough levels and serum creatinine. The survey of the NICUs in the United States demonstrated significant inconsistency in gentamicin monitoring practice.
CONCLUSION: Obtaining gentamicin trough levels guided by risk factors is more appropriate than obtaining routine trough levels in low-risk term neonates.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27537855     DOI: 10.1038/jp.2016.120

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  28 in total

1.  Once-daily gentamicin dosing for the preterm and term newborn: proposal for a simple regimen that achieves target levels.

Authors:  Anne Hansen; Peter Forbes; Alana Arnold; Edward O'Rourke
Journal:  J Perinatol       Date:  2003-12       Impact factor: 2.521

2.  Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates.

Authors:  L M L Stolk; P L J Degraeuwe; F H M Nieman; M C de Wolf; A de Boer
Journal:  Ther Drug Monit       Date:  2002-08       Impact factor: 3.681

3.  Validation of a dosage individualization table for extended-interval gentamicin in neonates.

Authors:  Deonne Dersch-Mills; Albert Akierman; Belal Alshaikh; Kamran Yusuf
Journal:  Ann Pharmacother       Date:  2012-06-26       Impact factor: 3.154

4.  Performance of a dosage individualization table for extended interval gentamicin in neonates beyond the first week of life.

Authors:  Deonne Dersch-Mills; Albert Akierman; Belal Alshaikh; Arun Sundaram; Kamran Yusuf
Journal:  J Matern Fetal Neonatal Med       Date:  2015-06-05

5.  Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants > or = 2500 g.

Authors:  Ghanshyam Agarwal; Alok Rastogi; Suma Pyati; Angela Wilks; Rosita S Pildes
Journal:  J Perinatol       Date:  2002-06       Impact factor: 2.521

6.  Development of criteria for gentamicin monitoring in a neonatal intensive care unit.

Authors:  Leslie M Stach; Eugenia Pallotto; Tracy L Sandritter
Journal:  Am J Health Syst Pharm       Date:  2012-08-01       Impact factor: 2.637

7.  Evaluation of gentamicin pharmacokinetics and dosing protocols in 195 neonates.

Authors:  J E Murphy; M L Austin; R F Frye
Journal:  Am J Health Syst Pharm       Date:  1998-11-01       Impact factor: 2.637

8.  A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates.

Authors:  Robert DiCenzo; Alan Forrest; Judianne C Slish; Carol Cole; Ronnie Guillet
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

9.  Extended-interval aminoglycoside administration for children: a meta-analysis.

Authors:  Despina G Contopoulos-Ioannidis; Nikos D Giotis; Dimitra V Baliatsa; John P A Ioannidis
Journal:  Pediatrics       Date:  2004-07       Impact factor: 7.124

10.  "Random" gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens.

Authors:  Elaine M Boyle; Isobel Brookes; Kathy Nye; Mike Watkinson; F Andrew I Riordan
Journal:  BMC Pediatr       Date:  2006-03-17       Impact factor: 2.125

View more
  1 in total

1.  Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin.

Authors:  J E Constance; D Reith; R M Ward; A Balch; C Stockmann; E K Korgenski; E A Thorell; C M T Sherwin
Journal:  J Perinatol       Date:  2017-06-08       Impact factor: 2.521

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.